ClinicalTrials.gg
CompletedNCT06680505Updated Nov 8, 2024

Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder

A Phase 2 interventional study of YZJ-1139 10mg and YZJ-1139 20mg in Insomnia Disorder, sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd.. Completed at 33 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Shanghai Haiyan Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 2 months after the study started (first participant enrolled Aug 2019, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Enrollment
18th of 162
300 · median 88
Started
2019
with 6 others
Phase 2
2 of 198
1 open now
Registered
129th of 198
by date
Lead sponsor
9 of 198
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 18th largest by enrollment of the 162 interventional ones that give a count, is one of 7 that started in 2019, is one of 2 in phase 2, and was the 129th registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy and safety of YZJ-1139 in the short-term treatment of primary chronic insomnia, explore the optimal effective dose, and provide the basis for phase III clinical trials

03

Conditions studied

  • Insomnia Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 to \< 65 years.
  2. Meet the clinical diagnostic criteria for primary chronic insomnia disorder as defined in ICSD-3 criteria.
  3. PSG results for 2 consecutive nights during the run-in period should meet the following conditions:
  1. The mean LPS of 2 nights is ≥ 30 min, with the LPS ≥ 15 min for any night; 2) And/or the mean WASO of 2 nights is ≥ 30 min, with neither night ≥20 min; 3) The mean SE of 2 nights is ≤ 85%, with the SE ≤ 87.5% for both nights. 4. During the study, the patient agreed to follow the daily bedtime between 9 and 12 pm , stayed in bed for 6.5-9 hours every night, and agreed to refrain from taking a nap.
  1. Female subjects are confirmed to be non-pregnant at screening; both men of and women of should agree to use medically acceptable and effective throughout the study and within 1 month after the end of the study.
  1. Understand the study procedures and contents, voluntarily participate in the clinical study and sign the written Form (ICF), have good compliance during participation in the study, and are willing to attend the visits

Exclusion criteria

Exclusion Criteria:

  1. Sleep disorders associated with neurological disorders such as depression, anxiety, sleep disorders due to dementia; depression: Hamilton Depression Scale (HAMD) score ≥ 18 or item 3 (suicidal ideation) score of 3 or more; anxiety: Hamilton Anxiety Scale (HAMA) score ≥ 14; dementia: scale score ≤ 20 for primary school, ≤ 22 for secondary school (including technical secondary school), and ≤ 23 for college (including junior college).
  2. Apnea-hypopnea index [AHI] and/or periodic limb movement index [PLMI] > 10 times/hour detected by PSG monitoring during the run-in period.
  3. Patients with severe endocrine diseases, blood diseases, cardiovascular and cerebrovascular diseases, diseases, respiratory function impairment and other related diseases.
  4. Previous history of nervous system disorders such as epilepsy, schizophrenia, bipolar mental disorder, neurodevelopmental retardation, cognitive disorder, narcolepsy, and restless leg syndrome.
  5. Receiving any hypnotics, antidepressants, antipsychotics, anticholinergics, memory-enhancing drugs, antihistamines, inducers, CYP3A inhibitors within 2 weeks prior to the start of the lead-in PSG.
  6. History of drug taking or addiction, which is known through questioning.
  7. Have any lifestyle that interferes with the study process or may interfere with sleep: for example, there will be travels across zones within the next 2 weeks or during the study period, or there will be shift work (night and daytime shift).etc.
  8. Special occupants who need to operate machinery during the test period, such as professional drivers, high-altitude operators, etc.
  9. Subjects who were treated with any other approved or insomnia medication prior to the study, including other orexin receptor inhibitors, or specific herbal preparations, traditional Chinese medicines, and still needed to continue in the study.
  10. and ALT > 2 × the (ULN), or Cr > 1.5 × ULN, or white blood cells \< lower limit of normal.
  11. Hyperthyroidism or hypothyroidism.
  12. History of alcohol abuse (defined as regular daily alcohol consumption exceeding the following criteria: approximately 720 mL of beer, or 240 mL of wine, or 60 mL of liquor).
  13. History of drug abuse , or positive urine drug screening (screening and/or baseline) for any indicator.
  14. Regular daily consumption of excessive tea and coffee drinks.
  15. Patients who have participated in other drug clinical trials within the past 3 months, or participated in other research trials during this trial.
  16. Pregnant or lactating women.
  17. History of allergy to the investigational product or its components.
  18. Have other conditions that make the subject unsuitable for participation in the clinical study in the opinion of the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    YZJ-1139 10mg

    Drug: YZJ-1139 10mg

  • Experimental
    YZJ-1139 20mg

    Drug: YZJ-1139 20mg

  • Experimental
    YZJ-1139 40mg

    Drug: YZJ-1139 40mg

  • Experimental
    YZJ-1139 60mg

    Drug: YZJ-1139 60mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Sleep efficiency (SE) monitored by PSG

    SE is the percentage of the subject 's total sleep time versus the monitored time;Changes from baseline (mean of any consecutive 2 days from Day -7 to Day -1) were evaluated separately for all subjects on Day 1 / Day 2, Day 13 / Day 14 of dosing, and for 1/5 subjects in each group on Day 27 / Day 28 of dosing.

    Time frame: Baseline , for all subjects: Day 1 / Day 2,Day 13 / Day 14; for 1/5 subjects: Day 27 / Day 28

Secondary outcomes

  1. Total sleep time (TST), sleep latency (LPS), sleep wake time (WASO), number of sleep awakenings (NAW) monitored by PSG

    Changes from baseline (mean of any consecutive 2 days from Day -7 to Da y -1) were evaluated separately for all subjects on Day 1 / Day 2, Day 13 / Day 14 of dosing, and for 1/5 subjects in each group on Day 27 / Day 28 of dosing.

    Time frame: Baseline ; for all subjects: Day 1 / Day 2, Day 13 / Day 14; for 1/5 subjects: Day 27 / Day 28

  2. Evaluation of Sleep Structures Recorded by PSG Monitoring

    To evaluate changes from baseline on Day 1 and Day 14 of dosing in all subjects and Day 28 of dosing in 1/5 subjects in each group

    Time frame: Baseline, for all subjects: Day 1, Day 14; for 1/5 subjects: Day 28

  3. Subjective Total Sleep Time (sTST), Subjective Sleep Latency (sTSO) Recorded by Sleep Diary

    The mean value at Week 1 and Week 2 for all subjects and the mean value at Week 4 for 1/5 subjects in each group were evaluated for the changes from the baseline value (mean value during the run-in period)

    Time frame: Baseline, for all subjects: Week 1,Week 2, for 1/5 subjects:Week 4

  4. Total sleep time (TST), sleep latency (SL), sleep awakening time (WASO), number of sleep awakenings (NAW) and sleep efficiency (SE) recorded by body movement recorder

    According to the index values measured by body movement recorder, the mean value at Week 1, mean value at Week 2 and mean value at Week 4 of medication for 1/5 subjects in each group were taken from all subjects to evaluate the change values from the baseline values (mean value during run-in period), respectively

    Time frame: Baseline, for all subjects:Week 1,Week 2, for 1/5 subjects:Week 4

  5. Insomnia Severity Index (ISI)

    Changes from baseline were evaluated separately for all subjects on Day 14 of dosing and for 1/5 subjects in each group on Day 28 of dosing

    Time frame: Baseline, for all subjects: Day 14, for 1/5 subjects:Day 28

  6. Rebound evaluation and proportion of rebound patients

    All subjects should receive body movement recorder test and sleep diary during the follow-up period, and each indicator will be compared with the baseline period. If the baseline value is reached or worse than the baseline value, it is defined as rebound

    Time frame: Follow-up Period, 7 days after double-blind treatment.

07

Study locations

33 sites
  • Beijing HuiLongGuan Hospital
    Beijing, China
  • Peking University People's Hospital
    Beijing, China
  • Xuanwu Hospital, Capital Medical University
    Beijing, China
  • The First Affiliated Hospital of Bengbu Medical College
    Bengbu, China
  • The First Hospital of Jilin University
    Changchun, China
  • Hunan Brain Hospital
    Changsha, China
  • Xiangya Hospital, Central South University
    Changsha, China
  • West China Hospital, Sichuan University
    Chengdu, China
  • Army Specialty Medical Center
    Chongqing, China
  • Guangdong Provincial People's Hospital
    Guangzhou, China
  • Nanfang Hospital of Southern Medical University (Department of Psychiatry)
    Guangzhou, China
  • Nanfang Hospital, Southern Medical University (Sleep Medicine Center)
    Guangzhou, China
  • The First Affiliated Hospital of Jinan University
    Guangzhou, China
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, China
  • The Affiliated Hospital of Jiujiang University
    Jiujiang, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, China
  • The First People's Hospital of Yunnan Province
    Kunming, China
  • Jiangxi Provincial Psychiatric Hospital
    Nanchang, China
  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing
    Nanjing, China
  • The First People 's Hospital of Nantong
    Nantong, China
  • Qingdao Municipal Hospital
    Qingdao, China
  • The Second Affiliated Hospital of Fujian Medical University
    Quanzhou, China
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, China
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, China
  • The Second Affiliated Hospital of Soochow University
    Suzhou, China
  • Tianjin Anding Hospital
    Tianjin, China
  • Wuhan Mental Health Center
    Wuhan, China
  • Tangdu Hospital, Fourth Military Medical University, PLA
    Xi'an, China
  • The Second Affiliated Hospital of Xinxiang Medical University
    Xinxiang, China
  • Henan Provincial People's Hospital
    Zhengzhou, China
  • The Affiliated Hospital of Zunyi Medical College
    Zunyi, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Sep 2020, 13 months.

Of 27 industry-sponsored phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 16. This study's 13 months is close to that.

Counting every sponsor, half of 63 studies reached it within 17 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2024
First posted
Nov 8, 2024
StartActual
Aug 4, 2019
Primary completionActual
Sep 30, 2020
CompletionActual
Mar 29, 2021
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06680505
Lead sponsor
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 8, 2024
Start date
Aug 4, 2019
Primary completion
Sep 30, 2020
Completion
Mar 29, 2021
Last update
Nov 8, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazamorexant

Start the discussion